6533b82cfe1ef96bd128f77c
RESEARCH PRODUCT
How bilastine is used to treat allergic rhinitis and urticaria in children
Esther Ballester AsensioPablo Rodríguez Del RíoFernando Rodríguez FernándezMiguel Tortajada-girbéssubject
Histamine H1 Antagonists Non-Sedatingmedicine.medical_specialtyAdolescentUrticariaSecond Generation Antihistaminesmedicine.medical_treatmentImmunologychemistry.chemical_compoundDouble-Blind MethodPiperidinesPharmacokineticsHumansImmunology and AllergyMedicineRoutine clinical practiceChildBilastinebusiness.industryRhinitis AllergicDermatologyTreatment OutcomeOncologychemistryPharmacodynamicsBenzimidazolesAntihistaminebusinessdescription
Management guidelines for allergic rhinitis and urticaria recommend oral second-generation antihistamines as first-line treatment. The efficacy and safety of bilastine, the newest nonsedating second-generation antihistamine, are well established in adolescents/adults with these allergic conditions. The bilastine development program for pediatric use (2–<12 years) followed EMA-authorized processes. Pharmacokinetic/pharmacodynamic simulation and modeling and a pharmacokinetic study were conducted to identify and confirm the pediatric dose (10 mg/day). A Phase III, multicenter, double-blind, randomized, placebo-controlled, parallel-group study was performed to confirm the safety of bilastine 10 mg/day in children. In this article, evidence is reviewed for use of bilastine in children with allergic rhinoconjunctivitis or urticaria. Several cases are presented which demonstrate its role in routine clinical practice.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-12-02 | Immunotherapy |